384 related articles for article (PubMed ID: 33184844)
1. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis.
Uzawa A; Kuwabara S; Suzuki S; Imai T; Murai H; Ozawa Y; Yasuda M; Nagane Y; Utsugisawa K
Clin Exp Immunol; 2021 Mar; 203(3):366-374. PubMed ID: 33184844
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.
Li Y; Guptill JT; Russo MA; Massey JM; Juel VC; Hobson-Webb LD; Howard JF; Chopra M; Liu W; Yi JS
Exp Neurol; 2019 Feb; 312():43-50. PubMed ID: 30472069
[TBL] [Abstract][Full Text] [Related]
3. Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.
Yilmaz V; Oflazer P; Aysal F; Durmus H; Poulas K; Yentur SP; Gulsen-Parman Y; Tzartos S; Marx A; Tuzun E; Deymeer F; Saruhan-Direskeneli G
PLoS One; 2015; 10(4):e0123546. PubMed ID: 25893403
[TBL] [Abstract][Full Text] [Related]
4. Intrathymic Tfh/B Cells Interaction Leads to Ectopic GCs Formation and Anti-AChR Antibody Production: Central Role in Triggering MG Occurrence.
Zhang X; Liu S; Chang T; Xu J; Zhang C; Tian F; Sun Y; Song C; Yi W; Lin H; Li Z; Yang K
Mol Neurobiol; 2016 Jan; 53(1):120-131. PubMed ID: 25407929
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.
Yi JS; Guidon A; Sparks S; Osborne R; Juel VC; Massey JM; Sanders DB; Weinhold KJ; Guptill JT
J Autoimmun; 2014 Aug; 52():130-8. PubMed ID: 24378287
[TBL] [Abstract][Full Text] [Related]
6. An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients.
Villegas JA; Van Wassenhove J; Le Panse R; Berrih-Aknin S; Dragin N
Ann N Y Acad Sci; 2018 Feb; 1413(1):154-162. PubMed ID: 29405352
[TBL] [Abstract][Full Text] [Related]
7. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.
Stathopoulos P; Kumar A; Nowak RJ; O'Connor KC
JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878127
[TBL] [Abstract][Full Text] [Related]
8. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.
Hurst RL; Gooch CL
Curr Neurol Neurosci Rep; 2016 Jul; 16(7):61. PubMed ID: 27170368
[TBL] [Abstract][Full Text] [Related]
9. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
10. CD4
Çebi M; Durmus H; Aysal F; Özkan B; Gül GE; Çakar A; Hocaoglu M; Mercan M; Yentür SP; Tütüncü M; Yayla V; Akan O; Dogan Ö; Parman Y; Saruhan-Direskeneli G
Front Immunol; 2020; 11():809. PubMed ID: 32508812
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of immunopathological features of AChR/MuSK autoantibody-negative myasthenia gravis.
Hayashi A; Shiono H; Ohta M; Ohta K; Okumura M; Sawa Y
J Neuroimmunol; 2007 Sep; 189(1-2):163-8. PubMed ID: 17706794
[TBL] [Abstract][Full Text] [Related]
12. [Myasthenia gravis induced by autoantibodies against MuSK].
Shigemoto K; Konishi T; Ohta M
Nihon Rinsho; 2008 Jun; 66(6):1149-54. PubMed ID: 18540361
[TBL] [Abstract][Full Text] [Related]
13. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis.
Aricha R; Mizrachi K; Fuchs S; Souroujon MC
J Autoimmun; 2011 Mar; 36(2):135-41. PubMed ID: 21193288
[TBL] [Abstract][Full Text] [Related]
14. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms.
Berrih-Aknin S; Le Panse R
J Autoimmun; 2014 Aug; 52():90-100. PubMed ID: 24389034
[TBL] [Abstract][Full Text] [Related]
15. Complement and cytokine based therapeutic strategies in myasthenia gravis.
Tüzün E; Huda R; Christadoss P
J Autoimmun; 2011 Sep; 37(2):136-43. PubMed ID: 21636248
[TBL] [Abstract][Full Text] [Related]
16. T cells and cytokines in the pathogenesis of acquired myasthenia gravis.
Milani M; Ostlie N; Wang W; Conti-Fine BM
Ann N Y Acad Sci; 2003 Sep; 998():284-307. PubMed ID: 14592887
[TBL] [Abstract][Full Text] [Related]
17. Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients.
Takata K; Stathopoulos P; Cao M; Mané-Damas M; Fichtner ML; Benotti ES; Jacobson L; Waters P; Irani SR; Martinez-Martinez P; Beeson D; Losen M; Vincent A; Nowak RJ; O'Connor KC
JCI Insight; 2019 Jun; 4(12):. PubMed ID: 31217355
[TBL] [Abstract][Full Text] [Related]
18. [Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis].
Ohta R; Motomura M
Rinsho Byori; 2014 Mar; 62(3):255-60. PubMed ID: 24800501
[TBL] [Abstract][Full Text] [Related]
19. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
Vincent A; Leite MI
Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
[TBL] [Abstract][Full Text] [Related]
20. Antigen specific B cells in myasthenia gravis patients.
Takata K; Kinoshita M; Mochizuki H; Okuno T
Immunol Med; 2020 Jun; 43(2):65-71. PubMed ID: 32046601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
